8 March 2021 at 1.15pm (EET)
CapMan Buyout invests in food supplement and medical device specialist Pharmia
CapMan Buyout invests in Pharmia, a leading food supplement and medical devices specialist in Finland. CapMan acquires a majority equity share in the company, with the owner family of Pharmia retaining a significant share.
Pharmia specialises in contract manufacturing and development of food supplements and CE-marked medical devices. The product portfolio consists of vitamins and minerals, probiotics, as well as CE-marked flu treatment products. Pharmia’s customers include well-known pharmaceutical and food supplement companies, pharmacies and wholesalers in the field in Finland and abroad. Founded in 1993, the family business today employs 90 people.
“Pharmia’s success is a great growth story of a family business. Long-term customer relations, talented personnel and strong product development have kept the company on a stable growth path. With our participation, growth can be further accelerated both organically and through acquisitions”, says Anders Björkell, Partner at CapMan Buyout.
“Food supplements and medical devices are an industry full of opportunities, and we have been following its development for a long time. We are very pleased to start cooperating with the leading company in the field”, Björkell continues.
“Pharmia has been an important part of our family’s life since it was founded 28 years ago by Ph.D. Tuulikki Harmia-Pulkkinen. Pharmia has been a pioneer in Finland in providing development, manufacturing and consulting services to both pharmaceutical and food supplement operators. Today, these industries form a significant business in Finland, with more than a dozen operating companies”, says Kari Pulkkinen, Chairman of the Pharmia board.
“For us, the future trends in the industry and the strengthening of international growth were the main reasons to choose this new ownership arrangement. In this interesting and developing industry, CapMan offers a strong foundation for utilising the know-how that has accumulated in Pharmia during a generation”, Pulkkinen continues.
“CapMan’s participation as a committed major shareholder is beneficial to our long-term customers and personnel, as well as to the entire industry. This arrangement enables significant growth in the international market and, together with the company’s growth goals, will offer interesting opportunities to the experts in the field,” says Hannu Vakkari, CEO of Pharmia.
Pharmia is the second investment of the CapMan Buyout XI fund, which was established in 2019. The transaction is expected to close by the end of March 2021.
For more information, please contact:
Anders Björkell, Partner, CapMan Buyout, tel. +358 40 5377 566
Kari Pulkkinen, Chairman of the Board, Pharmia, tel. +358 50 344 2605
Hannu Vakkari, CEO, Pharmia, tel. +358 50 065 0790
CapMan is a leading Nordic private asset expert with an active approach to value creation. We offer a wide selection of investment products and services. As one of the Nordic private equity pioneers, we have developed hundreds of companies and real estate assets and created substantial value in these businesses and assets over the past 30 years. With close to €4 billion in assets under management, our objective is to provide attractive returns and innovative solutions to investors. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover Private Equity, Real Estate and Infra. We also have a growing service business that includes procurement services, wealth management, and analysis, reporting and back office services. Altogether, CapMan employs around 150 people in Helsinki, Stockholm, Copenhagen, London and Luxembourg. We are a public company listed on Nasdaq Helsinki since 2001 and a signatory of the UN Principles for Responsible Investment (PRI) since 2012. Read more at www.capman.com
Pharmia is the first company in its field in Finland specializing in contract manufacturing and services. Initially, we operated strongly in the pharmaceutical industry, e.g. in clinical trials, but today we are focused on the development and manufacturing of food supplements and medical devices (CE marked products). Product development expertise and innovation, efficient production processes, high quality and a customer-oriented operating model have made us a leading operator in Finland. Our customers are mainly domestic, and we manufacture a large part of our country’s most respected brands in the industry. In addition, our products specifically for flu prevention and respiratory care are already exported directly or indirectly to more than 40 countries. Our premises are located in Tuusula, in a recently completely renovated property. Pharmia’s turnover is around 16 MEUR and we employ around 90 talented professionals. Our values are customer orientation, expertise and appreciation towards our colleagues, stakeholders, and society. The development and manufacture of high-quality and safe products that promote health and well-being is rewarding and meaningful, and we feel we contribute to both the success of our customers and the quality of life of our consumers. Read more at pharmia.fi/en/